Major study shows that adults with respiratory syncytial virus-associated acute respiratory infection face a 2.7-fold higher ...

In recent developments, a class action lawsuit was filed against Cerevel Therapeutics, Bain Capital Investors, and Pfizer ...

GlaxoSmithKline (GSK) and Pfizer filed a stipulation to dismiss with prejudice GSK’s litigation in the United States District ...

Pfizer's 7.5% dividend yield, strong R&D innovation, and defensive market position make it a smart buy. Read here for an ...

Pfizer's complaint is that GSK and a Quebec, Canada-based subsidiary ID Biomedical are causing "commercial uncertainty" for its own RSV vaccine programme with the three patents, which Pfizer says ...

Pfizer has bolstered the evidence behind its respiratory syncytial virus (RSV) vaccine with a positive trial of the shot used to protect newborns, adding to earlier results in older adults. The ...

Health secretary Robert F. Kennedy Jr. has expressed another unorthodox view on vaccines, declaring that single antigen ...

Learn more about whether Moderna, Inc. or Zai Lab Limited is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

NEW YORK, April 01, 2025--Pfizer Inc. (NYSE ... for ABRYSVO®, the company’s bivalent respiratory syncytial virus (RSV) prefusion F (RSVpreF) vaccine, to extend the indication to include ...

Pfizer and GlaxoSmithKline have agreed to end a lawsuit over alleged patent infringement involving their competing ...